ASCO24: Another win for Opdivo/Yervoy in first-line HCC despite uncertainties

The prognostic factor(s) driving outcomes at the initial stages of hepatocellular carcinoma remain unclear, complicating the treatment choice.

Related Posts

Signal: Danaher’s $5.7bn acquisition of Abcam faces sta...

Sep 15, 2023

Opinion: What does it mean to be ‘in recovery’? We need...

Jul 12, 2023

Runimotamab by Genentech USA for Solid Tumor: Likelihoo...

Dec 22, 2023